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Use of the dendritic cell marker, B and T lymphocyte 
attenuator, to identify functionally distinct subsets of 
human CD1c+ dendritic cells
Gary Reynolds, Paul Milne, Venetia Bigley, Collin Matthew, John Dudley Isaacs, Catharien Hilkens, Muzlifah Haniff a
Abstract 
Background Dendritic cells specialise in initiating adaptive immune responses. The CD1c+ subset in human beings 
is proposed to excel at CD4+ T cell priming. An equivalent population in mice has been shown to be heterogeneous 
and contain functionally distinct monocyte-related and conventional dendritic cell-related subpopulations. We aimed 
to examine whether analogous diversity exists in human beings using the conserved conventional dendritic cell 
marker, B and T lymphocyte attenuator (BTLA), which exhibits bimodal expression on CD1c+ dendritic cells.
Methods BTLA–CD1c+ and BTLA+CD1c+ dendritic cells were fl ow-sorted from peripheral blood. Gene expression 
(NanoString, Seattle, WA, USA), cytokine production after stimulation with lipopolysaccharide and R848 (Luminex, 
eBioscience, San Diego, CA, USA), and naive CD4+ T cell polarisation capacity (allogeneic mixed lymphocyte reaction 
assay) were compared. Their potential to diff erentiate into Langerhans cells (by culturing in granulocyte macrophage 
colony stimulating factor [GM-CSF] plus BMP7) and osteoclasts (by culturing in macrophage colony stimulating 
factor plus RANKL) in vitro was assessed. Their relative proportions in healthy blood and rheumatoid arthritis 
synovial fl uid were compared by fl ow cytometry.
Findings CD1c+BTLA– dendritic cells had higher expression than CD1c+BTLA+ dendritic cells of typical monocyte 
genes (CD14, FCGR2A, S100A8, S100A9); they preferentially promoted interferon γ (mean 17·79% [SE 3·69] vs 7·21 
[1·20], p=0·0094), interleukin (IL) 17 (5·10% [0·96] vs 2·30 [0·77], p=0·0015), and GM-CSF-producing T cells (34·39% [8·65] 
vs 18·31 [7·16], p=0·0066) and produced more IL1β (2517 pg/mL [241] vs 702·6 [206·4], p<0·0001) and IL18 (71·7 pg/mL 
[4·97] vs 48·07 [3·11], p=0·0016). CD1c+BTLA+ dendritic cells had higher expression than CD1c+BTLA– dendritic cells 
of conventional dendritic cell genes (CLEC9A, CD24, KIT) and preferentially promoted IL4-producing T cells (15·7% 
[2·06%] vs 11·7 [1·65], p=0·0059) and CD25hiFOXP3+ regulatory T cells (Tregs) (15·09% [4·18] vs 9·26 [2·48], p=0·0346). 
CD1c+BTLA– dendritic cells had greater potential to diff erentiate into tartrate-resistant acid phosphatase positive 
multinucleated osteoclasts whereas CD1c+BTLA+ dendritic cells preferentially diff erentiated into langerin+CD1a+ 
Langerhans cells. The ratio of CD1c+BTLA– to CD1c+BTLA+ dendritic cells was signifi cantly higher in rheumatoid 
arthritis synovial fl uid than in peripheral blood (3·76 [0·64] vs 1·11 [0·10], p<0·0001).
Interpretation CD1c-expressing dendritic cells have been regarded as a single population but these data demonstrate 
underlying complexity. CD1c+BTLA– dendritic cells support T helper (Th) 1 cell and Th17 cell responses and possess 
osteoclast potential. CD1c+BTLA+ dendritic cells support Th2 cell and Treg responses and possess Langerhans cell 
potential. The bulk CD1c+ population has previously been manipulated to produce vaccine and tolerogenic dendritic 
cell therapies in cancer and autoimmunity, but more refi ned targeting could potentially improve their effi  cacy.
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